Table 1 socio-demographic characteristics of patients who developed severe adverse effects in the Democratic Republic of Congo, over the 2003–2017 period
Parameters Category | Mean ± SD or Me (IQR) | N (%) |
|---|---|---|
Age (years) | 38.6 ± 15.5 | |
Sex | ||
Male | 670 (70.9) | |
Female | 275 (29.1) | |
Patient’s health status | ||
Onchocerciasis | ||
Confirmed | 0 (0.0) | |
Suspected | 936 (99.1) | |
Negative | 9 (0.9) | |
Loiasis | ||
Confirmed | 857 (90.7) | |
Suspected | 30 (3.2) | |
Negative | 58 (6.1) | |
Schistomiasis | ||
Confirmed | 0 (0.0) | |
Suspected | 3 (0.3) | |
Negative | 942 (99.7) | |
Lymphatic filariasis | ||
Confirmed | 0 (0.0) | |
Suspected | 3 (0.3) | |
Negative | 942 (99.7) | |
Information on the last treatment | ||
Ivermectin dosage (number of tablets per patient) | 3.6 ± 0.6 | |
Hemp consumption 24 h before ivermectin treatment | 110 (11.6) | |
Alcohol consumption 24 h before ivermectin treatment | 206 (26.3) | |
Microfilaraemia (mf/ml) upon admission | 1200 (440–14,400) | |
Onset of adverse effects (hours) | 24 (8–96) | |
Duration of hospitalisation (days) | 7 (5–10) | |
Status at discharge | ||
Recovery | 890 (94.2) | |
Death | 55 (5.8) | |